Cancer-associated fibroblasts’ functional heterogeneity in pancreatic ductal adenocarcinoma

Mohammad Awaji, Rakesh K Singh

Research output: Contribution to journalReview article

3 Citations (Scopus)

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is a leading cause of cancer-related deaths in the USA. Desmoplasia and inflammation are two major hallmarks of PDAC. Desmoplasia, composed of extracellular matrix (ECM), cancer-associated fibroblasts (CAFs), and infiltrating immune and endothelial cells, acts as a biophysical barrier to hinder chemotherapy and actively contributes to tumor progression and metastasis. CAFs represent a multifunctional subset of PDAC microenvironment and contribute to tumor initiation and progression through ECM deposition and remodeling, as well as the secretion of paracrine factors. Attempts to resolve desmoplasia by targeting CAFs can render an adverse outcome, which is likely due to CAFs heterogeneity. Recent reports describe subsets of CAFs that assume more secretory functions, in addition to the typical myofibroblast phenotype. Here, we review the literature and describe the relationship between CAFs and inflammation and the role of the secretory-CAFs in PDAC.

Original languageEnglish (US)
Article number290
JournalCancers
Volume11
Issue number3
DOIs
StatePublished - Mar 1 2019

Fingerprint

Adenocarcinoma
Extracellular Matrix
Inflammation
Neoplasms
Myofibroblasts
Cancer-Associated Fibroblasts
Endothelial Cells
Neoplasm Metastasis
Phenotype
Drug Therapy

Keywords

  • Cancer-associated fibroblast
  • CXCL8
  • IL-6
  • Inflammation
  • Myofibroblast
  • Pancreatic cancer
  • PDAC
  • TGF-β

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Cancer-associated fibroblasts’ functional heterogeneity in pancreatic ductal adenocarcinoma. / Awaji, Mohammad; Singh, Rakesh K.

In: Cancers, Vol. 11, No. 3, 290, 01.03.2019.

Research output: Contribution to journalReview article

@article{0cc8f9e0207443f08e2d0e3bc3d38d5e,
title = "Cancer-associated fibroblasts’ functional heterogeneity in pancreatic ductal adenocarcinoma",
abstract = "Pancreatic ductal adenocarcinoma (PDAC) is a leading cause of cancer-related deaths in the USA. Desmoplasia and inflammation are two major hallmarks of PDAC. Desmoplasia, composed of extracellular matrix (ECM), cancer-associated fibroblasts (CAFs), and infiltrating immune and endothelial cells, acts as a biophysical barrier to hinder chemotherapy and actively contributes to tumor progression and metastasis. CAFs represent a multifunctional subset of PDAC microenvironment and contribute to tumor initiation and progression through ECM deposition and remodeling, as well as the secretion of paracrine factors. Attempts to resolve desmoplasia by targeting CAFs can render an adverse outcome, which is likely due to CAFs heterogeneity. Recent reports describe subsets of CAFs that assume more secretory functions, in addition to the typical myofibroblast phenotype. Here, we review the literature and describe the relationship between CAFs and inflammation and the role of the secretory-CAFs in PDAC.",
keywords = "Cancer-associated fibroblast, CXCL8, IL-6, Inflammation, Myofibroblast, Pancreatic cancer, PDAC, TGF-β",
author = "Mohammad Awaji and Singh, {Rakesh K}",
year = "2019",
month = "3",
day = "1",
doi = "10.3390/cancers11030290",
language = "English (US)",
volume = "11",
journal = "Cancers",
issn = "2072-6694",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "3",

}

TY - JOUR

T1 - Cancer-associated fibroblasts’ functional heterogeneity in pancreatic ductal adenocarcinoma

AU - Awaji, Mohammad

AU - Singh, Rakesh K

PY - 2019/3/1

Y1 - 2019/3/1

N2 - Pancreatic ductal adenocarcinoma (PDAC) is a leading cause of cancer-related deaths in the USA. Desmoplasia and inflammation are two major hallmarks of PDAC. Desmoplasia, composed of extracellular matrix (ECM), cancer-associated fibroblasts (CAFs), and infiltrating immune and endothelial cells, acts as a biophysical barrier to hinder chemotherapy and actively contributes to tumor progression and metastasis. CAFs represent a multifunctional subset of PDAC microenvironment and contribute to tumor initiation and progression through ECM deposition and remodeling, as well as the secretion of paracrine factors. Attempts to resolve desmoplasia by targeting CAFs can render an adverse outcome, which is likely due to CAFs heterogeneity. Recent reports describe subsets of CAFs that assume more secretory functions, in addition to the typical myofibroblast phenotype. Here, we review the literature and describe the relationship between CAFs and inflammation and the role of the secretory-CAFs in PDAC.

AB - Pancreatic ductal adenocarcinoma (PDAC) is a leading cause of cancer-related deaths in the USA. Desmoplasia and inflammation are two major hallmarks of PDAC. Desmoplasia, composed of extracellular matrix (ECM), cancer-associated fibroblasts (CAFs), and infiltrating immune and endothelial cells, acts as a biophysical barrier to hinder chemotherapy and actively contributes to tumor progression and metastasis. CAFs represent a multifunctional subset of PDAC microenvironment and contribute to tumor initiation and progression through ECM deposition and remodeling, as well as the secretion of paracrine factors. Attempts to resolve desmoplasia by targeting CAFs can render an adverse outcome, which is likely due to CAFs heterogeneity. Recent reports describe subsets of CAFs that assume more secretory functions, in addition to the typical myofibroblast phenotype. Here, we review the literature and describe the relationship between CAFs and inflammation and the role of the secretory-CAFs in PDAC.

KW - Cancer-associated fibroblast

KW - CXCL8

KW - IL-6

KW - Inflammation

KW - Myofibroblast

KW - Pancreatic cancer

KW - PDAC

KW - TGF-β

UR - http://www.scopus.com/inward/record.url?scp=85063398151&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85063398151&partnerID=8YFLogxK

U2 - 10.3390/cancers11030290

DO - 10.3390/cancers11030290

M3 - Review article

VL - 11

JO - Cancers

JF - Cancers

SN - 2072-6694

IS - 3

M1 - 290

ER -